CN111235155A - Composition for qualitative analysis of mesenchymal stem cell membrane protein, method and application - Google Patents
Composition for qualitative analysis of mesenchymal stem cell membrane protein, method and application Download PDFInfo
- Publication number
- CN111235155A CN111235155A CN202010086517.2A CN202010086517A CN111235155A CN 111235155 A CN111235155 A CN 111235155A CN 202010086517 A CN202010086517 A CN 202010086517A CN 111235155 A CN111235155 A CN 111235155A
- Authority
- CN
- China
- Prior art keywords
- cells
- composition
- membrane protein
- mesenchymal stem
- analysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 108010052285 Membrane Proteins Proteins 0.000 title claims abstract description 39
- 102000018697 Membrane Proteins Human genes 0.000 title claims abstract description 34
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 24
- 238000004451 qualitative analysis Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 72
- 238000004458 analytical method Methods 0.000 claims abstract description 28
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 7
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 claims abstract description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 22
- 239000002609 medium Substances 0.000 claims description 21
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 claims description 17
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 claims description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 14
- 238000003384 imaging method Methods 0.000 claims description 14
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 11
- 239000001569 carbon dioxide Substances 0.000 claims description 11
- 238000011065 in-situ storage Methods 0.000 claims description 11
- 239000012091 fetal bovine serum Substances 0.000 claims description 10
- 239000012148 binding buffer Substances 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 9
- 230000001066 destructive effect Effects 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000012205 qualitative assay Methods 0.000 claims 1
- 238000011895 specific detection Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 18
- 108091023037 Aptamer Proteins 0.000 description 13
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- 238000010609 cell counting kit-8 assay Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001262 western blot Methods 0.000 description 7
- 102100032912 CD44 antigen Human genes 0.000 description 6
- 239000011535 reaction buffer Substances 0.000 description 6
- 108010087230 Sincalide Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000012202 endocytosis Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000004445 quantitative analysis Methods 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 208000037280 Trisomy Diseases 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- VBUWJOHKCBQXNU-IUYQGCFVSA-N 2-deoxy-D-ribonic acid Chemical compound OC[C@@H](O)[C@@H](O)CC(O)=O VBUWJOHKCBQXNU-IUYQGCFVSA-N 0.000 description 1
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000035362 autoimmune disorder of the nervous system Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A composition for qualitative analysis of mesenchymal stem cell membrane protein comprises an oligodeoxyribonucleotide chain shown in SEQ ID No 1, wherein a fluorescent group is marked at the 5' terminal of the oligodeoxyribonucleotide chain. The invention realizes the nondestructive analysis of the target cell membrane protein by recognizing the membrane protein of the cell through the DNA chain and obtaining the amplified fluorescent signal, can be customized according to the specific detection requirements of the target cell (such as mesenchymal stem cells and even membrane proteins on the surfaces of other different types of cells), meets the actual requirements of different analyses, and has good application potential.
Description
Technical Field
The invention relates to a composition for detection, in particular to a composition for qualitatively detecting protein, which realizes the nondestructive analysis of mesenchymal stem cell membrane protein.
Background
Mesenchymal cells (MSCs) originate from embryonic mesodermal stem cells and are widely present throughout the body. Among them, mesenchymal stem cells belong to a class of pluripotent stem cells of mesoderm, are mainly present in connective tissues and organ mesenchyme, are concentrated in bone marrow and adipose tissues, and have various potentials. Under certain conditions, it can be induced to differentiate into different types of cells in vivo and in vitro, such as: chondrocytes, osteoblasts, adipocytes, nerve cells, cardiac muscle cells, and the like. It is easy to separate and culture and has high in vitro amplification potential. Clinical experiments prove that the mesenchymal stem cell transplantation can be used for tissue repair and treatment of mesenchymal tissue genetic defect diseases, and is an attractive treatment tool. The CD44 protein is a group of membrane integrins which are widely distributed and have the molecular weight of (85-160) multiplied by 10kD in a multi-molecular form, mediates the interaction between cells and extracellular matrix, and has higher expression ratio of CD44 in various tumor cells than that of corresponding normal tissues, and is related to the tumorigenicity, invasiveness and lymphatic metastasis of the tumor cells. Therefore, the analysis of the mesenchymal stem cell membrane protein marker CD44 can provide a lot of important information for clinical judgment of various bone diseases, lung injuries, diabetes, nervous system diseases, autoimmune diseases and other diseases.
There are many methods for detecting CD44 protein, but they are all conventional methods such as Immunofluorescence (IF), immunoblotting (WB) and Mass Spectrometry (MS). Immunoblotting and mass spectrometry methods, while providing quantitative information about proteins, are destructive to cells and require lysis of cells and prior extraction of proteins. Immunofluorescence is a powerful immunochemical technique that allows the in situ, non-structurally destructive detection of a variety of membrane proteins by fluorophore-modified antibodies. However, this method requires irreversible labeling of the target protein with an antibody, which may unpredictably affect the activity of the membrane protein and the cells. DNA is short for deoxyribonucleic acid (deoxyribonic acid), and has unique advantage in the aspect of constructing a functional structure on a nanometer scale as a natural biological macromolecule. Since the DNA nanotechnology is proposed, the DNA nanotechnology has the characteristics of structural programmability, good biocompatibility and biostability, no obvious cytotoxicity and immunostimulation, capability of entering cells autonomously and the like, has attracted wide attention in the field of biomedicine, and is already used for imaging and detecting tumors.
Disclosure of Invention
One object of the present invention is to provide a composition containing a fluorescently modified DNA strand for use in qualitative analysis of in situ imaging of a target cell membrane protein.
Another object of the present invention is to provide a composition comprising a fluorescence-modified DNA strand, which is bound to a membrane protein of a mesenchymal stem cell, such that the expression of the membrane protein and the activity of the cell are not affected, thereby achieving a non-destructive analysis.
It is yet another object of the present invention to provide a cellular method of analysis that allows qualitative analysis of in situ imaging of the target cell membrane protein CD44 in a sample.
It is still another object of the present invention to provide a kit for performing qualitative analysis of in situ imaging of target cell membrane protein CD44 in a sample.
The target cell of the present invention is a generic term for the cell to be detected contained in the sample, such as: but are not limited to, somatic cells, stem cells, cancer cells, and the like.
A composition, comprising:
the oligodeoxyribonucleotide chain shown in SEQ ID No. 1 has a 5' terminal labeled with a fluorophore (e.g., a red fluorophore Cy 5).
Another composition comprising
An aptamer primer (Apt-Pri) shown as SEQ ID No. 1, wherein a red fluorescent group (such as Cy5) is marked at the 5' end of the aptamer primer;
an auxiliary primer (Ass-Pri) shown as SEQ ID No. 2;
a circular DNA template (LOOP) shown as SEQ ID No. 3;
the 5 'end and the 3' end of the Molecular Beacon (MB) shown as SEQ ID No4 are respectively modified with a green fluorescent group FAM and a quenching group BHQ.
The various compositions of the present invention further comprise chlorpromazine hydrochloride (CPM), 1mg/mL BSA, 10 v/v% Fetal Bovine Serum (FBS), 4.5g/L glucose, 5mM MgCl2And DMEM medium, etc., which are used alone and in combination in the present invention.
The present invention provides various compositions further comprising:
DNA polymerase (Klenow Fragment, 3 '→ 5' exo)-) For amplification and extension of the 3' end,
a DNA polymerase buffer, and
dNTP。
in the composition, the sequence of the oligodeoxynucleotide Apt-Pri is as follows:
5′-ccaaggcctgcaagggaaccaaggacacagacctcacgaccattctgc；
in the composition of the invention, the sequence of the oligodeoxynucleotide Ass-Pri is as follows:
ctaacaattatcactgggtcgtgaggt；
in the composition of the present invention, the sequence of oligodeoxynucleotide LOOP is:
gtacggcagaatcagtgataattgttagaagaaaaaaaaatcccaacccgccctaccct；
in the composition of the present invention, the sequence of oligodeoxynucleotide MB is:
cgctctcccaacccgccctagagcg。
according to the composition, the detected target cell is mesenchymal stem cell, and the membrane protein is CD 44.
The composition is used for qualitative analysis of in-situ imaging of the mesenchymal stem cell membrane protein CD44, and the method comprises the following steps:
firstly, dissolving a CD44 protein aptamer (Apt-Pri) into a buffer (such as Phosphate Buffered Saline (PBS)) and heating to 95 ℃ for 5 minutes to denature the aptamer, and then cooling to room temperature to form a DNA secondary structure;
thereafter, to prevent endocytosis of the aptamer, 100 μ M chlorpromazine hydrochloride (CPM) was added to the medium and incubated with the cells in a carbon dioxide thermostated cell incubator for 30 minutes;
next, the CPM-containing medium was gently washed twice with buffer to remove the CPM, and then an aptamer-protein binding buffer (containing 1mg/mL BSA, 10 v/v% FBS, 4.5g/L glucose, 5mM MgCl) containing 150nM Apt-Pri was added2DMEM) and cells were incubated at 37 ℃ for 60 minutes;
and finally, imaging under a confocal laser scanning microscope to realize qualitative analysis of in-situ imaging of the target cell membrane protein.
The composition can also be used for ectopic fluorescence quantitative analysis of the mesenchymal stem cell membrane protein CD44, and the method comprises the following steps:
firstly, a mixture of Apt-Pri, Ass-Pri and Loop is heated for 5 minutes at 95 ℃ in a buffer solution (such as Phosphate Buffered Saline (PBS)) to denature the mixture, and then the mixture is cooled to room temperature to complement the mixture into a DNA three-body complex structure;
thereafter, to prevent endocytosis of the aptamer, 100 μ M chlorpromazine hydrochloride (CPM) was added to the medium and incubated with the cells in a carbon dioxide thermostated cell incubator for 30 minutes;
next, the CPM-containing medium was gently washed twice with buffer, and then 100. mu.L of RCA reaction buffer containing 150 nmRNA trisomy complex (i.e., 2. mu.L of 10mM dNTPs, 2. mu.L of 5U/. mu.L DNA polymerase, 10. mu.L of 10 XPase reaction buffer, 5. mu.L of 10. mu.M molecular beacon, and 81. mu.L of DMEM) and the cells were incubated for 2 hours;
and finally, collecting the supernatant to detect the intensity of the fluorescence signal, thereby realizing the ectopic fluorescence quantitative analysis of the target cell membrane protein.
The composition is used for performing nondestructive analysis on the mesenchymal stem cell membrane protein CD44, and the method comprises the following steps:
firstly, a mixture of Apt-Pri, Ass-Pri and Loop is heated for 5 minutes at 95 ℃ in a buffer solution (such as Phosphate Buffered Saline (PBS)) to denature the mixture, and then the mixture is cooled to room temperature to complement the mixture into a DNA three-body complex structure;
thereafter, to prevent endocytosis of the aptamer, 100 μ M chlorpromazine hydrochloride (CPM) was added to the medium and incubated with the cells in a carbon dioxide thermostated cell incubator for 30 minutes;
then, incubating the aptamer-protein binding buffer containing 150nM DNA trisomy complex and the cells at 37 ℃ for 60 minutes to realize qualitative analysis of in-situ imaging of target cell membrane proteins;
then, washing off the aptamer-protein binding buffer solution by using PBS, adding RCA reaction buffer solution and incubating the cells for 2 hours, and collecting the supernatant to detect the intensity of a fluorescence signal so as to realize quantitative analysis of ectopic fluorescence of the target cell membrane protein;
finally, the analyzed cells were subjected to Western blotting (Western Blot) and CCK-8(CellCounting Kit-8) to detect changes in membrane protein expression and cell activity.
Finally, the target cell membrane protein is analyzed without damage.
The technical scheme of the invention has the following beneficial effects:
the detection composition disclosed by the invention realizes in-situ imaging qualitative and ectopic fluorescence quantitative analysis on target cells in a sample by adopting a signal amplification system mediated by Rolling Circle Amplification (RCA) and combined with a trisomy complex formed by DNA complementation and a target membrane protein.
The detection composition can select aptamers of different target cell membrane proteins according to detection requirements, and can be applied to analysis and detection of different target cell membrane proteins by selecting the membrane proteins with characteristics, so that the detection composition has good universality.
The composition is convenient to operate, can realize complete lossless analysis of cells and membrane proteins thereof, and can be widely applied to the fields of clinical diagnosis, disease monitoring and the like.
Drawings
FIG. 1 is a schematic diagram of the principle of the composition of the present invention for non-destructive analysis of mesenchymal stem cell membrane proteins;
FIG. 2 is an image of different cells under a confocal laser scanning microscope;
FIG. 3 shows the quantification of membrane proteins for different cell number assays;
FIG. 4 is a graph showing the results of protein expression measurement by Western blotting;
FIG. 5 is a diagram showing the results of the measurement of cell activity by the CCK-8 method.
Detailed Description
The technical scheme of the invention is described in detail in the following with reference to the accompanying drawings. Although the present invention has been described in detail with reference to the preferred embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the spirit and scope of the invention as defined in the appended claims.
Example 1 qualitative detection of mesenchymal Stem cell Membrane proteins
The aptamer primers (Apt-Pri) were denatured by heating at 95 ℃ for 5 minutes, and then cooled to room temperature to form a DNA secondary structure. In the glass bottom confocal culture dish, the culture dish is 1 multiplied by 105The individual cells were seeded. For better adherent growth of cells, the cells were cultured in a carbon dioxide incubator at 37 ℃ for 24 hours. To prevent endocytosis of the aptamer, 150 μ L of 100 μ M chlorpromazine hydrochloride was added to the medium and incubated with the cells for 30 minutes in a carbon dioxide thermostated cell incubator.
The medium containing chlorpromazine hydrochloride was removed by washing twice with 1 XPBS, and then 150. mu.L of aptamer-protein binding buffer (containing 1mg/mL Bovine Serum Albumin (BSA), 10 v/v% Fetal Bovine Serum (FBS), 4.5g/L glucose and 5mM magnesium chloride (MgCl) containing 150nM aptamer primer (Apt-Pri) was added2) The serum-free double-antibody-containing high-sugar medium (DMEM) and the cells were incubated in a carbon dioxide incubator at 37 ℃ for 60 minutes. The medium containing aptamer-protein binding buffer was removed by washing twice with 1 × PBS and 1mL of PBS was added. Finally, imaging under a confocal laser scanning microscope to realize qualitative analysis of in-situ imaging of target cell membrane proteins, as shown in fig. 2.
Example 2 quantitative detection of mesenchymal Stem cells
The principle of analyzing mesenchymal stem cell membrane protein with the composition (e.g., Apt-Pri, etc.) provided in this example is shown in FIG. 1. The specific implementation mode is as follows:
a mixture of aptamer primers (Apt-Pri), helper primers (Ass-Pri), and circular DNA template (LOOP) was denatured by heating at 95 ℃ for 5 minutes, and then slowly cooled to room temperature to complement it into a DNA triplet complex structure. 1X 10 per culture dish in 24-well plates4The cells were inoculated and cultured in a carbon dioxide incubator at 37 ℃ for 24 hours for better adherent growth. To prevent endocytosis of the aptamer, 150. mu.L of 100. mu.M chlorpromazine hydrochloride (CPM) was added to the medium (e.g., DMEM medium) and incubated with the cells in a carbon dioxide thermostated cell incubator for 30 minutes. CPM-containing medium was removed by gentle washing twice with 1 XPBS, and then 100. mu.L of Rolling Circle Amplification (RCA) reaction buffer containing 150NM DNA trisomy complex, containing 2. mu.L of 10mM deoxyribonucleoside triphosphates (dNTPs), 2. mu.L of 5U/. mu.LDNA polymerase, 10. mu.L of 10 XPase reaction buffer, 5. mu.L of 10. mu.M Molecular Beacon (MB) and 81. mu.L of High-sugar medium (DMEM, High Glucose) containing 10% Fetal Bovine Serum (FBS) and diabody, and cells were incubated for 2 hours. And finally, collecting the RCA reaction buffer solution, and detecting the intensity of a fluorescence signal by using a fluorescence spectrophotometer to realize the ectopic fluorescence quantitative analysis of the target cell membrane protein. As can be seen in fig. 3, the detection limit is 10 cells.
Example 3 non-destructive analysis of mesenchymal Stem cell Membrane proteins
Three groups of mesenchymal stem cells, three groups of HepG2 and L02 cells were prepared, and the CD44 protein of the three cells of the first group was assayed by a Western blotting (Western Blot) experiment. The second set of three cells was then subjected to the first round of analysis as described in example 2 above, and the cells after the analysis were subjected to western blot assay. Then, the first round of analysis was performed on the three cells of the second group by the same method as in example 2, the cells after the analysis were placed in a carbon dioxide constant temperature cell incubator and cultured for 2 hours, and after the cells became stable, the second round of analysis was continued by the same method as in example 2, and the cells after the analysis were subjected to western blotting experimental determination. The results are shown in FIG. 4: compared with the group which is not analyzed, the expression amount of the cell membrane protein which is analyzed in the first round and the second round is not obviously changed, which shows that the analysis method adopting the composition of the embodiment does not influence the expression of the cell membrane protein.
Example 4 non-destructive analysis of mesenchymal Stem cell Membrane proteins Effect on cellular Activity
Three groups of mesenchymal stem cells, HepG2 and L02 were prepared, and the cells were divided into 1X 10 cells4The cells were seeded in 96-well plates at a density of one cell per well and were cultured for 24 hours in a carbon dioxide incubator at 37 ℃ for better adherent growth. Medium (Ab) without any reagent addition and medium with cells (Ac) were used as blank and control, respectively. The medium containing the cells and subjected to the total nondestructive analysis was used As an experimental group (As). After 48 hours of culture, the first group of three cells was assayed by the CCK-8 method (Cell Counting Kit-8). The second set of three cells was then subjected to the first round of analysis as described in example 2 above, and the cells after the end of the analysis were subjected to the CCK-8 assay. The cells of the second group were subjected to the first round of analysis by the same method as in example 2, the cells after the analysis were placed in a carbon dioxide-isothermal cell incubator and cultured for 2 hours, and after the cells were stabilized, the second round of analysis was carried out by the same method as in example 2, and the cells after the analysis were measured by the CCK-8 method. The results are shown in FIG. 5: the cell activities of the first and second rounds of analysis did not change significantly compared to the non-analyzed group, indicating that the assay using the composition of this example did not affect the cell activities.
The CCK-8 method comprises the following steps: 10 μ LCCK-8 reagent was added to each well and cells were incubated continuously for 2h at 37 ℃. Finally, the OD value was assessed by absorbance measurement at 450nm by a microplate reader. The assay was repeated three times and the cell viability was calculated as follows:
cell viability (%) - [ (As-Ab)/(Ac-Ab) ] × 100%.
Sequence listing
<110> official business
CHINA STEM CELL GROUP SHANGHAI BIOTECHNOLOGY Co.,Ltd.
CHONGQING STEM CELL TECHNOLOGY Co.,Ltd.
CHINA STEM CELL GROUP HAINAN BOAO AFFILIATED STEM CELL HOSPITAL Co.,Ltd.
SHANGHAI STEM CELL TECHNOLOGY Co.,Ltd.
SHAANXI STEM CELL TECHNOLOGY Co.,Ltd.
SOOCHOW STEM CELL TECHNOLOGY Co.,Ltd.
SANYA STEM CELL TECHNOLOGY Co.,Ltd.
<120> composition for qualitative analysis of mesenchymal stem cell membrane protein, method and application
<141>2020-02-03
<160>4
<170>SIPOSequenceListing 1.0
<210>1
<211>48
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
ccaaggcctg caagggaacc aaggacacag acctcacgac cattctgc 48
<210>2
<211>27
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
ctaacaatta tcactgggtc gtgaggt 27
<210>3
<211>59
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
gtacggcaga atcagtgata attgttagaa gaaaaaaaaa tcccaacccg ccctaccct 59
<210>4
<211>25
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
cgctctccca acccgcccta gagcg 25
Claims (12)
1. A composition characterized by comprising:
the oligodeoxyribonucleotide chain shown in SEQ ID No. 1 has a 5' terminal marked with a fluorescent group.
2. Composition according to claim 1, characterized in that it further comprises chlorpromazine hydrochloride.
3. The composition according to claim 1, characterized in that it further comprises a DMEM medium, and 1mg/mL BSA, 10 v/v% Fetal Bovine Serum (FBS), 4.5g/L glucose and 5mM MgCl2One or more of them.
4. The composition of claim 1, wherein said oligodeoxyribonucleotide strand is conjugated to a membrane protein CD 44.
5. The composition of claim 1, wherein the fluorophore is Cy 5.
6. Use of a composition according to any one of claims 1 to 5 in a qualitative assay for in situ imaging of target cells.
7. Use of the composition of any one of claims 1 to 5 in qualitative analysis of mesenchymal stem cell membrane protein CD 44.
8. Use of a composition according to any one of claims 1 to 5 in the non-destructive analysis of mesenchymal stem cells.
9. A kit comprising a composition according to any one of claims 1 to 5.
10. A method of performing a qualitative analysis of a target cell using the composition of any one of claims 1 to 5, comprising the steps of:
firstly, dissolving the oligodeoxyribonucleotide chain into a buffer solution, heating to 95 ℃ and keeping for 5 minutes to denature the oligodeoxyribonucleotide chain, and then cooling to room temperature to form a DNA secondary structure;
thereafter, 100 μ M CPM was added to the medium and incubated with the cells in a carbon dioxide thermostatted cell incubator for 30 minutes;
subsequently, the CPM-containing medium was removed by gently washing twice with buffer, and then the aptamer-protein binding buffer containing 150nM Apt-Pri and the cells were incubated at 37 ℃ for 60 minutes;
finally, imaging under a confocal laser scanning microscope to realize qualitative analysis of target cell membrane protein in-situ imaging;
the aptamer-protein binding buffer solution of Apt-Pri is a DMEM medium.
11. The method of claim 10, wherein the Apt-Pri aptamer-protein binding buffer comprises 4.5g/L glucose.
12. The method of claim 10, wherein the Apt-Pri aptamer-protein binding buffer comprises 1mg/mL BSA, 10 v/v% FBS, and 5mM MgCl2One or more of them.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010086517.2A CN111235155B (en) | 2020-02-10 | 2020-02-10 | Composition, method and application for qualitative analysis of mesenchymal stem cell membrane protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010086517.2A CN111235155B (en) | 2020-02-10 | 2020-02-10 | Composition, method and application for qualitative analysis of mesenchymal stem cell membrane protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111235155A true CN111235155A (en) | 2020-06-05 |
| CN111235155B CN111235155B (en) | 2024-03-22 |
Family
ID=70867053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010086517.2A Active CN111235155B (en) | 2020-02-10 | 2020-02-10 | Composition, method and application for qualitative analysis of mesenchymal stem cell membrane protein |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111235155B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130040837A1 (en) * | 2009-12-01 | 2013-02-14 | Brigham And Women's Hospital, Inc. | Aptamer cell compositions |
-
2020
- 2020-02-10 CN CN202010086517.2A patent/CN111235155B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130040837A1 (en) * | 2009-12-01 | 2013-02-14 | Brigham And Women's Hospital, Inc. | Aptamer cell compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111235155B (en) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020243978A1 (en) | Primer for specific detection of human source genomic dna and application thereof | |
| Brooks et al. | Ex vivo human adipose tissue derived mesenchymal stromal cells (ASC) are a heterogeneous population that demonstrate rapid culture-induced changes | |
| JP2021175415A (en) | Methods of preparing primary cell sample | |
| US10018633B2 (en) | Multi-aptamer-based, cell-specific, one-step tumor cell detection assays | |
| Lai et al. | A sensitive flow cytometric method for multi-parametric analysis of microRNA, messenger RNA and protein in single cells | |
| CN108430336A (en) | Circulating cells, the internal collection of protein and nucleic acid and Local Quantitative and signature analysis | |
| Young et al. | Muscle injury induces a transient senescence‐like state that is required for myofiber growth during muscle regeneration | |
| EP2460876B1 (en) | Method for identifying senescent mesenchymal stem cells | |
| CN111304312B (en) | Marker for identifying or assisting in identifying vascular cells and/or vascular cell senescence degree and application thereof | |
| KR101828812B1 (en) | Kit for Detecting Senescence of Stem cells | |
| CN111257567B (en) | Composition for quantitatively analyzing mesenchymal stem cell membrane protein, method and application thereof | |
| CN111239089B (en) | Method for nondestructive analysis of mesenchymal stem cell membrane protein | |
| CN111235155B (en) | Composition, method and application for qualitative analysis of mesenchymal stem cell membrane protein | |
| WO2019240073A1 (en) | Quantitative pcr probe | |
| CN113684256B (en) | Method for detecting multiple targets by multiple positioning based on green solvent and programmable oligonucleotide probe | |
| WO2011049439A1 (en) | Method for selecting bone forming mesenchymal stem cells | |
| CN110408620B (en) | Nucleic acid aptamer, obtaining method thereof, derivative thereof and application thereof | |
| EP3009521B1 (en) | Marker for detecting proliferation and treatment capacities of adipose-derived stem cell cultured in medium containing egf or bfgf, and use thereof | |
| JP2019007759A (en) | Method for evaluating aging degree and kit for evaluating aging degree | |
| JP2008524985A (en) | Stem cells, purification methods, identification methods and uses | |
| Matsushita et al. | Multi-omics analysis in developmental bone biology | |
| JP7001674B2 (en) | Markers and methods for quantifying the composition or purity of cell cultures and quantifying the identity of chondrocytes or synovial cells in vitro | |
| CN108929875B (en) | Method for separating embryonic stem cells and fixing embryonic stem cells on surface based on DNA aptamer | |
| CA2723950A1 (en) | Methods and reagents for the determination of telomere length in a semi-automatic manner of every single cell in a immobilized cell population | |
| CN113684255A (en) | Target positioning and quantitative detection method based on DNA spherical nanostructure imaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |